Abstract: A photocurable composition includes a photopolymerizable component and a photopolymerization initiator. When a test piece with 39 mm length, 8 mm width, and 4 mm thickness, is produced by photofabrication under conditions in which the photocurable composition is irradiated with visible light having 405 nm wavelength at 12 mJ/cm2 irradiation dose to form a cured layer with 100 m thickness, the cured layer is stacked in a thickness direction thereof to form a rectangular fabrication product with 39 mm length, 8 mm width, and 4 mm thickness, and the fabrication product is irradiated with ultraviolet rays having 365 nm wavelength at 10 J/cm2 irradiation dose to produce the test piece, a total fracture work of the test piece measured in compliance with ISO20795-1:2008 is 1100 J/m2 or more.

Abstract: The present invention relates to solriamfetol or novel salts thereof and its process for preparation. More particularly the present invention relates to solriamfetol dibenzoyl-D-tartaric acid salt or solriamfetol di-p-toluoyl-D-tartaric acid salt and their process for preparation. Further the present invention relates to use of solriamfetol dibenzoyl-D-tartaric acid salt or solriamfetol di-p-toluoyl-D-tartaric acid salt for the preparation of solriamfetol hydrochloride.

Abstract: The invention relates to 2-octylcyclopropyl-1-carboxylic acid, in particular in the form of one of the isomers thereof in isolated form or in the form of a mixture of at least two of said isomers. The invention further relates to a method for synthesizing 2-octylcyclopropyl-1-carboxylic acid or at least one of the isomers thereof. Finally, the invention relates to the use of 2-octylcyclopropyl-1-carboxylic acid or of one of said isomers in isolated form or of one of the mixtures of at least two of the isomers thereof, as a perfuming agent. The invention further relates to the compositions including 2-octylcyclopropyl-1-carboxylic acid or one of said isomers in isolated form or one of the mixtures of at least two of the isomers thereof, as a perfuming agent.

Abstract: The invention relates to novel compounds which are especially suitable for use as writing monomers in holographic media. The invention further provides a photopolymer and a holographic medium comprising the inventive compounds, and an optical display, a security document and a holographic optical element comprising an inventive holographic medium.

Abstract: An acrylic or methacrylic compound having N-alkoxyalkyl group; and a method for producing the compound. An acrylic or methacrylic compound having N-alkoxyalkyl group, of Formula [1]: [where R1 is a hydrogen atom or methyl group; R2 is a C2-20 alkylene group etc.; R3 is an r-valent C2-20 aliphatic group etc.; R4 is a C1-20 alkyl group etc.; Z is >NCOO— or —OCON< (where “-” is a bond, “>” and “<” each have two bonds, and any one of “>” and “<” is bonded to —CH2OR4); and r is a natural number of 2 or more and 9 or less].

Abstract: The invention provides compounds and methods, for example, to carry out organocatalytic Michael additions of aldehydes to cyclically constrained nitroethylene compounds catalyzed by a proline derivative to provide cyclically constrained ?-substituted-?-nitro-aldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96 to >99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to cyclically constrained protected ?-amino acid residues, which are essential for systematic conformational studies of ?-peptide foldamers. New methods are also provided to prepare other ?-amino acids and peptides. These new building blocks can be used to prepare foldamers, such as ?/?-peptide foldamers, that adopt specific helical conformations in solution and in the solid state.

Abstract: A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided.

Abstract: The present disclosure relates to a method for preparing a disubstituted urea and carbamate compounds simultaneously through a one-pot reaction of an amine, carbon dioxide and an alkylene oxide compound in the presence of an ionic liquid-based complex catalyst system containing indium. In accordance with the present disclosure, a disubstituted urea and carbamate compounds can be prepared simultaneously at high yield. In addition, the ionic liquid-based catalyst containing indium according to the present disclosure is economical because it can be reused several times.

Abstract: A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a composition for muscle relaxation containing the phenyl alkyl carbamate derivative compounds and/or pharmaceutically acceptable salt thereof as an active ingredient, and a method of muscle relaxation comprising administering a pharmaceutically effective amount of the phenyl alkyl carbamate derivative compound and/or a pharmaceutically acceptable salt thereof to a subject in need of to a subject in need of, are provided.

Abstract: A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided.

Abstract: The present invention relates to the cosmetic, dermatological or therapeutic use of certain cyclohexyl carbamate compounds of formula (I) given below, preferably as anti-cellulite actives.

Abstract: The present invention relates to a method of producing a carbamate compound, comprising reacting a fluorine-containing carbonic diester compound represented by formula (1) and a non-aromatic diamine compound represented by formula (2) without using a catalyst, to thereby produce a carbamate compound represented by formula (3), and a method of producing an isocyanate compound represented by formula (20) from the carbamate compound without using a catalyst, wherein R represents a fluorine-containing monovalent aliphatic hydrocarbon group, and A represents a divalent aliphatic hydrocarbon group, a divalent alicyclic hydrocarbon group or a divalent aromatic-aliphatic hydrocarbon group.

Abstract: The invention provides innovative blocked polyisocyanates whose crosslinking is initiated thermally and photochemically. The polyisocyanates comprise at least one thermally reversibly blocked NCO group whose blocking agent contains at least one group which on exposure to actinic radiation reacts, with polymerization, with ethylenically unsaturated compounds. A process for preparing the polyisocyanates, and their use in binders, is also provided.

Abstract: Alkyl and/or alkenyl glycerol carbamate prepared by reacting a carbonate selected from the group consisting of glycerol carbonate, diglycerol carbonate, polyglycerol carbonate and mixtures thereof, with an amine of the general formula (I): HNR1R2??(I) wherein R1 represents a hydrogen atom or a hydrocarbon group selected from the group consisting of alkyl groups and alkenyl groups having from 1 to 22 carbon atoms and R2 represents a hydrocarbon group selected from the group consisting of alkyl groups and alkenyl groups having from 4 to 22 carbon atoms, and cyclic alkyl groups having 5 or 6 carbon atoms, are described along with methods for their use as pearlizing agents in surface-active preparations.

Abstract: The present invention relates to a method of producing a carbamate compound, comprising reacting a fluorine-containing carbonic diester compound represented by formula (1) and a non-aromatic diamine compound represented by formula (2) without using a catalyst, to thereby produce a carbamate compound represented by formula (3), and a method of producing an isocyanate compound represented by formula (20) from the carbamate compound without using a catalyst, wherein R represents a fluorine-containing monovalent aliphatic hydrocarbon group, and A represents a divalent aliphatic hydrocarbon group, a divalent alicyclic hydrocarbon group or a divalent aromatic-aliphatic hydrocarbon group.

Abstract: The invention provides a fluoro-containing ether monomer for fabricating contact lenses represented by following formula (I): In formula (I), R10 is fluoroalkyl group (CxFyHz, wherein x is an integer of 2-20, y to is an integer of 5-30, and y+z=2x+1), R11 is oxygen, nitrogen or sulfur; R12 is C1-C3 alkylene; n is an integer of 3-40.

Abstract: The present invention relates to a (meth)acrylated compound (A) prepared from: (i) a polyol constituent, (ii) a polyacid constituent and (iii) one or more (meth)acrylating compounds, wherein the polyol constituent comprises at least 30% by weight of one or more cyclic ether polyols, relative to the total weight of the polyol constituent, and wherein the compound (A) optionally further contains one or more moieties selected from the group consisting of (poly)caprolactone-containing moieties (ai), (poly)lactide- and/or (poly)glycolide-containing moieties (aii), moieties providing epoxide groups (aiii) and moieties providing alkylene oxide groups containing from 2 to 4 carbon atoms (aiv). The compounds of the invention are in particular suited for the making of radiation curable coating compositions and inks less prone to migration.

Abstract: The problem to be solved is to produce, at high yields with high purity, anhydrous crystals of a compound represented by formula (1) that is an important intermediate for preparation of FXa inhibitor compound (X) or a pharmacologically acceptable salt thereof, or a hydrate thereof. The solution thereto is an industrial preparation process that provides, with high purity, anhydrous crystals of a compound represented by the following formula (1), which is an intermediate for the production of FXa inhibitor compound (X) or a pharmacologically acceptable salt thereof, or a hydrate thereof, wherein Boc represents a tert-butoxycarbonyl group.

Abstract: The present invention provides redox drug derivatives. In particular, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, (3R,4R,5S)-4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester, (3S)-3-(aminomethyl)-5-methylhexanoic acid, (3S)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-?-?-diphenyl-3-pyrrolidineacetamide, (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane-1-carboxylic acid and (2R,3R,4S)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid redox derivatives.

Abstract: Described is a resinous article of manufacture that is wrinkle-resistant and is warpage-resistant when subjected to very high temperatures. Such an article is useful as an optical lens.

Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.

Abstract: A urethane adhesive composition includes a first liquid and a second liquid, the first liquid containing a prepolymer obtained by reacting a polyisocyanate and a high-molecular-weight polyol (I), and at least one filler selected from talc and calcium carbonate, and containing 20 parts by mass or more of talc, 0 to 40 parts by mass of calcium carbonate, and 10 parts by mass or more of zeolite based on 100 parts by mass of the polyisocyanate, the high-molecular-weight polyol (I), and the prepolymer in total, the second liquid containing a high-molecular-weight polyol (II) and a low-molecular-weight polyol, the ratio of the number of moles of hydroxyl groups derived from the low-molecular-weight polyol to the total number of moles of hydroxyl groups derived from the high-molecular-weight polyol (I) and the high-molecular-weight polyol (II) being four or more.

Abstract: The present invention provides methods of making and using peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH). The present invention provides compounds and compositions that suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). The present invention also sets forth methods for inhibiting FAAH as well as methods for treating conditions such as, but not limited to, pain, inflammation, immune disorders, dermatitis, mucositis, the over reactivity of peripheral sensory neurons, neurodermatitis, and an overactive bladder. Accordingly, the invention also provides compounds, methods, and pharmaceutical compositions for treating conditions in which the selective inhibition of peripheral FAAH (as opposed to CNS FAAH) would be of benefit.

Abstract: Non-fluorinated blocked polyurethanes are described as extenders and, particularly as textile auxiliaries, for use with fluorochemical polymers in treating substrates, for example fibrous substrates, such as textile fabrics or yarns. The polyurethane is prepared by reacting a polyisocyanate, a blocking agent, and a non-fluorinated isocyanate reactive compound having an average alkyl chain length of 24 to 50 carbon atoms.

Abstract: Surface-modified zirconia nanoparticles and methods for making and using the same are provided. The surface-modifiers include non-metallic organic derivatives, comprising at least one hydroxamate functionality, wherein at least some of the non-metallic organic derivatives are attached to at least some of the zirconia nanoparticles.

Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity.

Abstract: Catalysts, which are free of tin, are described which are useful in the reaction between an isocyanate and an alcohol, which is a key step for preparing polyurethane polymers. The catalyst is a metal complex or salt of formula (1): [Zn(L1)l1(L2)l2(Y)x]??(1) in which: l1?1 and l2=0 or 1; with l1+l2=2, x=1 or 2, the symbol L1 represents a ligand which is a ?-dicarbonylato anion or the enolate anion of a ?-dicarbonyl compound or an acetylacetato anion derived from a ?-ketoester, when l1=2, the symbols L1 are identical or different, the symbol L2 represents an anionic ligand which is different from L1, and the symbol Y represents a neutral ligand; where the metal complex or salt C of formula (1) is not zinc diacetylacetonate.

Abstract: Disclosed is an adamantanamine derivative which is useful as a significant intermediate of an 11?HSD-1 inhibitor. Disclosed is a compound represented by the formula (II): wherein R10 is a group represented by the formula: —(CR13R14)m-NR12—R11 or the like.

Abstract: A method to form a urethane material, the method comprises blending and reacting at least one isocyanate, at least one isocyanate reactive compound and a metallized polyhedral oligomeric silsesquioxane to provide said urethane material, the metallized polyhedral oligomeric silsesquioxane is a dimeric structure with general formula wherein M represents a metal providing a 6-coordinated metal center, x and y being 1, R1O and R2O represent an alkoxide bridging the 6-coordinated metal centers, R3OH and R4OH represent an alcohol ligand and each of R5, to R18 is selected from the group consisting of alkyl-, polyether- and polyester ligands.

Abstract: The disclosure provides curable inks including a diurethane gelator having the structure of Formula I. wherein R and R? each, independently of the other, is a C1-C22 saturated aliphatic hydrocarbon group selected from the group consisting of (1) linear aliphatic groups, (2) branched aliphatic groups, (3) cyclic aliphatic groups, (4) aliphatic groups containing both cyclic and acyclic portions, any carbon atom of the saturated aliphatic hydrocarbon group may be optionally substituted with an alkyl group (cyclic or acyclic), wherein (1) and (2) groups have a carbon number of from about 1 to about 22 carbons, and wherein (3) and (4) groups have a carbon number of from about 4 to about 10 carbons; and X is selected from the group consisting of: (i) an alkylene group, (ii) an arylene group, (iii) an arylalkylene group, and (iv) an alkylarylene group.

Abstract: Cyclosporin derivatives, methods of manufacturing the cyclosporin derivatives and methods for treating subjects infected with certain viruses, including hepatitis virus or HIV by administering the cyclosporin derivatives are described.

Abstract: Cyclosporin derivatives, methods of manufacturing the cyclosporin derivatives and methods for treating subjects infected with certain viruses, including hepatitis virus or HIV by administering the cyclosporin derivatives are described.

Abstract: The disclosure provides a diurethane gelator having the structure of Formula I. wherein R1 and R1? each, independently of the other, is a C1-C22 saturated aliphatic hydrocarbon group selected from the group consisting of (1) linear aliphatic groups, (2) branched aliphatic groups, (3) cyclic aliphatic groups, (4) aliphatic groups containing both cyclic and acyclic portions, any carbon atom of the saturated aliphatic hydrocarbon group may be optionally substituted with an alkyl group (cyclic or acyclic), wherein (1) and (2) groups have a carbon number of from about 1 to about 22 carbons, and wherein (3) and (4) groups have a carbon number of from about 4 to about 10 carbons; and X is selected from the group consisting of: (i) an alkylene group, (ii) an arylene group, (iii) an arylalkylene group, and (iv) an alkylarylene group.

Abstract: Methods of catalyzing chemical reactions are provided. A tri-substituted phosphine having at least one substituent that is an alkyl group is added as a catalyst to reaction mixtures. Reaction mixtures contain uretdiones, anhydrides, or isocyanate functional materials including isocyanurates, in various combinations with hydroxyl, thiol, and/or amine functional materials. Curable compositions comprising these catalysts and reaction mixtures are also provided.

Abstract: Described herein is a composition comprising at least one of: X—R—(Z)n wherein X is selected from: an aziridine amide, an aziridine urea, an isocyanate, an alcohol, an amine, an epoxy, or a sulfhydryl, R is a multifunctional organic group, and Z is selected from —N3 or —C?C—R?, wherein R? is a hydrogen or a monofunctional organic group and n is from one to about 10. Also, described are mixtures, curable polymeric compositions, and methods of making cured polymeric compositions.

Abstract: The invention relates to low molecular mass products and to the use thereof as reversible or permanent low-temperature crosslinkers in Diels-Alder reactions.

Abstract: The present invention relates to a compound of the following general formula (I): R1—NH—CH(R2)—P(?O)(OR3)—CH2—C(R4)(R5)—CONH—CH(R6)—COOR7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R1 represents a —C(?O)—O—C(R8)(R9)—OC(?O)—R10 group; R2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R3 represents a hydrogen atom or a —C(R12)(R13)—OC(?O)—R14 group; R4 and R5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R4 represents a hydrogen atom and R5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substi

Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.

Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.

Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.

Abstract: Prepolymers, which are accessible from formamides of low molecular weight di- or triamines (formamide-terminated low molecular weight compounds) and di- or polyisocyanates, of the general formula (II): X—[—N(CHO)—CO—NH—R1—NCO]n??(II) wherein X represents a linear or branched aliphatic, cycloaliphatic, heterocyclic and/or aromatic structural unit having 2 to 40 carbon atoms, and which is optionally further substituted and/or optionally comprises one or more heteroatoms, wherein R1 represents an organic radical which may optionally contain one or more heteroatoms and which may further contain one or more additional free isocyanate groups and/or one or more urethane, biuret, carbodiimide, isocyanurate, allophanate, iminooxadiazinedione and/or uretdione structural units, and wherein n?2; processes for making the same; compositions containing the same; and uses thereof.

Abstract: The invention relates to (per)fluoropolyether block copolymers comprising: A) a fluoropolyoxyalkylene segment (chain Ra) comprising one or more units of formula (CHXCF2CF2O)— in which X is hydrogen or fluorine; B) a (per)fluoropolyoxyalkylene segment (chain Rf), that is to say a segment comprising recurring units having at least one catenary ether bond and at least one fluorocarbon moiety, said (per)fluoropolyoxyalkylene segment being different from chain Ra and having a molecular weight higher than 400 g/mol. These copolymers are endowed with improves lubricant properties or with improved water and oil-repellence properties.

Abstract: To provide a method whereby a 2-azaadamantane can easily be obtained in good yield. A method for producing a 2-azaadamantane represented by the formula (1), which comprises cyclizing a compound represented by the following formula (2) in the presence of an acid.

Abstract: A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided.

Abstract: Hydrophilic, multi-arm urethane polymers are described that are dispersible and/or soluble in water, and provide wetting, foaming and cleaning benefits for aqueous cleaning products, including hard surface cleaners, machine dishwash, and liquid hand dishwash compositions.

Abstract: The present invention relates to compounds having the following structure: wherein R is H or OH and X+ is protonated metformin, protonated arginine, protonated lysine and protonated meglumine. The invention also relates to intermediates used in the preparation of such compounds, processes for the preparation of such compounds and intermediates, pharmaceutical compositions comprising such compounds and the methods of treatment using such compounds as antidiabetic, antiobesity, and antisarcopenia agents.

Abstract: An oligomer is made by capping a uretdione compound of structure with a compound (II) having an active hydrogen and a carbamate or cyclic carbonate group under conditions in which the isocyanate groups but not the uretdione group react. The product (III) is either reacted with a reactant having at least two active hydrogens under reaction conditions that cleave the uretdione ring, after which any cyclic carbonate groups may be converted to carbamate groups, or a product (III) having cyclic carbonate groups is reacted with ammonia or primary amine to provide uretdione with a hydroxy carbamate group that is then self-condensed under uretdione ring-opening conditions. A curable coating composition comprises the oligomer; a coated article is prepared by applying a layer of the curable coating composition and curing the applied layer.

Abstract: The invention relates to a process for the preparation of N-protected ?-aminoaldehydes by deacetalization of the acetal functional group of corresponding N-protected ?-aminoacetals using formic acid.

Abstract: Prepolymers are prepared by a reaction of a polyisocyanate and a hydroxylmethyl containing polyester polyol derived from a fatty acid. The prepolymers can be prepared having isocyanate, hydroxyl, or a variety of other reactive functional groups. The prepolymers are useful in making polyurethanes and other polymers, or a crosslinking agents.

Abstract: The present invention relates to an improved process for the preparation of (1S,3S,5S)-242(S)-2-amino-2-(3-hydroxy-1-adamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and its intermediates.